466 research outputs found
Enhancement of the antiproliferative activity of [RuCp(PPh3)2(dmoPTA-1κP)]+ via its coordination to one {CoCl2} unit: synthesis, crystal structure and properties of [RuCp(PPh3)2-μ- dmoPTA-1κP:2κ2N,N’-CoCl2](OTf)·0.25H2O.
Ciudad de migrantes: Estrategias museológicas
Este reporte explica la intervención que se llevó a cabo dentro del Museo de la Ciudad de Guadalajara, relacionada con museología, educación y nuevas formas de presentar la información a los públicos que visitan el museo. Es un proyecto transdisciplinario donde participaron estudiantes de psicología y arquitectura, con el objetivo en común de generar herramientas museológicas para hacer divertida e interesante la experiencia de los públicos al visitar el Museo, con la finalidad que la experiencia induzca a las personas a regresar o invitar a otros a visitar el espacio.ITESO, A.C
Ampliación de la distribución geográfica de cacomixtle tropical, bassariscus sumichrasti (carnivora: procyonidae) en méxico
El cacaomixtle tropical (Bassariscus sumichrasti: Saussure, 1860: Carnivora: Procyonidae) se distribuye desde el sureste de México hasta Panamá (COATESESTRADA y ESTRADA, 1986; EMMONS, 1999). Su hábitat son las selvas altas y medianas perennifolias, el bosque mesófilo de montaña y las áreas húmedas y densas de bosques de encino-pino, desde el nivel del mar hasta los 2.900 m. de altitud. La especie es simpátrica con el cacomixtle común (Bassariscus astutus: Lichtenstein, 1830) en algunas zonas de los estados de Guerrero, Veracruz y Oaxaca; se ha registrado en el sureste de México y en la Península de Yucatán (NAVA, 2005). La especie está incluida en el Apéndice III de CITES (Convention on International Trade in Endangered Species), en México está considerada como sujeta a protección especial por el Instituto Nacional de Ecología, en la norma oficial mexicana NOM-059-ECOL (DIARIO OFICIAL DE LA FEDERACIÓN, 2001
Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons
<p>Abstract</p> <p>Background</p> <p>Non-human primates are valuable models for the study of insulin resistance and human obesity. In baboons, insulin sensitivity levels can be evaluated directly with the euglycemic clamp and is highly predicted by adiposity, metabolic markers of obesity and impaired glucose metabolism (i.e. percent body fat by DXA and HbA<sub>1c</sub>). However, a simple method to screen and identify obese insulin resistant baboons for inclusion in interventional studies is not available.</p> <p>Methods</p> <p>We studied a population of twenty baboons with the euglycemic clamp technique to characterize a population of obese nondiabetic, insulin resistant baboons, and used a multivariate linear regression analysis (adjusted for gender) to test different predictive models of insulin sensitivity (insulin-stimulated glucose uptake = Rd) using abdominal circumference and fasting plasma insulin. Alternatively, we tested in a separate baboon population (n = 159), a simpler model based on body weight and fasting plasma glucose to predict the whole-body insulin sensitivity (Rd/SSPI) derived from the clamp.</p> <p>Results</p> <p>In the first model, abdominal circumference explained 59% of total insulin mediated glucose uptake (Rd). A second model, which included fasting plasma insulin (log transformed) and abdominal circumference, explained 64% of Rd. Finally, the model using body weight and fasting plasma glucose explained 51% of Rd/SSPI. Interestingly, we found that percent body fat was directly correlated with the adipocyte insulin resistance index (r = 0.755, p < 0.0001).</p> <p>Conclusion</p> <p>In baboons, simple morphometric measurements of adiposity/obesity, (i.e. abdominal circumference), plus baseline markers of glucose/lipid metabolism, (i.e. fasting plasma glucose and insulin) provide a feasible method to screen and identify overweight/obese insulin resistant baboons for inclusion in interventional studies aimed to study human obesity, insulin resistance and type 2 diabetes mellitus.</p
Synthesis and antiproliferative activity of [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (HdmoPTA = 3,7-H-3,7- dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)
Campaña de sensibilización para el proyecto Ciudad Amigable con los Mayores en Guadalajara, Jalisco: equipo de producción
El siguiente reporte, habla de las estrategias para dar continuidad al proyecto junto con la reedición de algunos contenidos que ya formaban parte de los productos a entregar y la creación de contenido nuevo y estrategias de comunicación realizadas a lo largo del periodo Verano 2018 para Alter Código, desarrollado por alumnos del Departamento de Estudios Socioculturales (DESO) del ITESO, este con el fin de crear una campaña de sensibilización para dignificar la imagen de los adultos mayores y difundir el proyecto Alter Código entre estudiantes y académicos. El objetivo de este proyecto fue mostrar una imagen digna e íntegra de grupos estructuralmente desfavorecidos con el fin de generar una visión variante de cómo se vive la vejez en los mayores. Esto representado con los productos audiovisuales que se pre produjeron este verano 2018, productos nuevos, contenido listo para difundir, así como trabajos y asesorías donde se trabajó la sensibilización del tema con los alumnos del escenario de adultos mayores. Partiendo de ahí, los resultados fueron una guía de estudio con los lineamientos aprobados para el uso en futuros alumnos, contenidos audiovisuales y gráficos, nuevos contenidos y una estrategia de comunicación en marcha.ITESO, A.C
The Palomar Testbed Interferometer Calibrator Catalog
The Palomar Testbed Interferometer (PTI) archive of observations between 1998
and 2005 is examined for objects appropriate for calibration of optical
long-baseline interferometer observations - stars that are predictably
point-like and single. Approximately 1,400 nights of data on 1,800 objects were
examined for this investigation. We compare those observations to an
intensively studied object that is a suitable calibrator, HD217014, and
statistically compare each candidate calibrator to that object by computing
both a Mahalanobis distance and a Principal Component Analysis. Our hypothesis
is that the frequency distribution of visibility data associated with
calibrator stars differs from non-calibrator stars such as binary stars.
Spectroscopic binaries resolved by PTI, objects known to be unsuitable for
calibrator use, are similarly tested to establish detection limits of this
approach. From this investigation, we find more than 350 observed stars
suitable for use as calibrators (with an additional being
rejected), corresponding to sky coverage for PTI. This approach
is noteworthy in that it rigorously establishes calibration sources through a
traceable, empirical methodology, leveraging the predictions of spectral energy
distribution modeling but also verifying it with the rich body of PTI's on-sky
observations.Comment: 100 pages, 7 figures, 7 tables; to appear in the May 2008ApJS, v176n
Tetranuclear Ru2Cu2 and Ru2Ni2 complexes with nanomolar anticancer activity.
[{RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2-N,N’-CuCl}2-μ-Cl-μ-
OCH3](CF3SO3)2·(CH3OH)4 (1) and [{RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2-
N,N’-NiCl}2-μ-Cl-μ-OH](CF3SO3)2 (2) have been synthesized and
characterized. Their antiproliferative activities were assessed against
six human solid tumours showing nanomolar GI50 values. The effects
of 1 and 2 on SW1573 cells colony formation, HeLa cells action
mechanism and their interaction with the pBR322 DNA plasmid were
evaluated
Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection
<p>Abstract</p> <p>Background</p> <p>Bovine dialyzable leukocyte extract (bDLE) is derived from immune leukocytes obtained from bovine spleen. DLE has demonstrated to reduce transcription of Human Immunodeficiency Virus Type 1 (HIV-1) and inactivate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Therefore, we decided to clarify the mode of antiviral action of bDLE on the inhibition of HIV-1 infection through a panel of antiviral assays.</p> <p>Results</p> <p>The cytotoxicity, HIV-1 inhibition activity, residual infectivity of bDLE in HIV-1, time of addition experiments, fusion inhibition of bDLE for fusogenic cells and the duration of cell protection even after the removal of bDLE were all assessed in order to discover more about the mode of the antiviral action.</p> <p>HIV-1 infectivity was inhibited by bDLE at doses that were not cytotoxic for HeLa-CD4-LTR-β-gal cells. Pretreatment of HIV-1 with bDLE did not decrease the infectivity of these viral particles. Cell-based fusion assays helped to determine if bDLE could inhibit fusion of Env cells against CD4 cells by membrane fusion and this cell-based fusion was inhibited only when CD4 cells were treated with bDLE. Infection was inhibited in 80% compared with the positive (without EDL) at all viral life cycle stages in the time of addition experiments when bDLE was added at different time points. Finally, a cell-protection assay against HIV-1 infection by bDLE was performed after treating host cells with bDLE for 30 minutes and then removing them from treatment. From 0 to 7 hours after the bDLE was completely removed from the extracellular compartment, HIV-1 was then added to the host cells. The bDLE was found to protect the cells from HIV-1 infection, an effect that was retained for several hours.</p> <p>Conclusions</p> <p>bDLE acted as an antiviral compound and prevented host cell infection by HIV-1 at all viral life cycle stages. These cell protection effects lingered for hours after the bDLE was removed. Interestingly, bDLE inhibited fusion of fusogenic cells by acting only on CD4 cells. bDLE had no virucidal effect, but could retain its antiviral effect on target cells after it was removed from the extracellular compartment, protecting the cells from infection for hours.</p> <p>bDLE, which has no reported side effects or toxicity in clinical trials, should therefore be further studied to determine its potential use as a therapeutic agent in HIV-1 infection therapy, in combination with known antiretrovirals.</p
- …